# SHINE Study Overview
Keywords: SPINRAZA, SMA, long-term study, safety, tolerability, efficacy, adverse events, RULM, HFMSE, CHOP INTEND

> The page provides detailed information about the SHINE study, a long-term open-label extension for SMA patients, focusing on the safety, tolerability, and efficacy of SPINRAZA treatment.

## Details
- [SHINE Study Overview](#): SHINE is a long-term study for SMA patients who previously participated in SPINRAZA trials, evaluating safety and efficacy.
- [Study Objectives](#): Primary focus on long-term safety and tolerability; secondary focus on long-term efficacy.
- [Safety Results](#): No new safety concerns observed; frequent adverse events included pyrexia, upper respiratory infections, and scoliosis.
- [Efficacy in Later-Onset Participants](#): Clinically meaningful improvements in motor function were achieved with SPINRAZA.
- [Assessment Tools](#): RULM, HFMSE, and CHOP INTEND are scales used to evaluate motor function and strength in SMA patients.
- [Clinical Study Programmes](#): Overview of SPINRAZA clinical trials and real-world evidence studies.
- [References](#): Citations and links to supporting studies and clinical data.
- [Adverse Event Reporting](#): Instructions for reporting adverse events in the UK and Ireland.